Alexander R Gawroński1, Yen-Yi Lin2,3, Brian McConeghy2,3, Stephane LeBihan2,3, Hossein Asghari1,3, Can Koçkan4, Baraa Orabi1,3, Nabil Adra5, Roberto Pili5, Colin C Collins2,3, S Cenk Sahinalp4, Faraz Hach2,3. 1. School of Computing Science, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada. 2. Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia V52 1M9, Canada. 3. Vancouver Prostate Centre, Vancouver, British Columbia V6H 3Z6, Canada. 4. Department of Computer Science, Indiana University, Bloomington 47405, USA. 5. School of Medicine, Indiana University, Indianapolis, 46202, USA.
Abstract
MOTIVATION: Cancer is a complex disease that involves rapidly evolving cells, often forming multiple distinct clones. In order to effectively understand progression of a patient-specific tumor, one needs to comprehensively sample tumor DNA at multiple time points, ideally obtained through inexpensive and minimally invasive techniques. Current sequencing technologies make the 'liquid biopsy' possible, which involves sampling a patient's blood or urine and sequencing the circulating cell free DNA (cfDNA). A certain percentage of this DNA originates from the tumor, known as circulating tumor DNA (ctDNA). The ratio of ctDNA may be extremely low in the sample, and the ctDNA may originate from multiple tumors or clones. These factors present unique challenges for applying existing tools and workflows to the analysis of ctDNA, especially in the detection of structural variations which rely on sufficient read coverage to be detectable. RESULTS: Here we introduce SViCT , a structural variation (SV) detection tool designed to handle the challenges associated with cfDNA analysis. SViCT can detect breakpoints and sequences of various structural variations including deletions, insertions, inversions, duplications and translocations. SViCT extracts discordant read pairs, one-end anchors and soft-clipped/split reads, assembles them into contigs, and re-maps contig intervals to a reference genome using an efficient k-mer indexing approach. The intervals are then joined using a combination of graph and greedy algorithms to identify specific structural variant signatures. We assessed the performance of SViCT and compared it to state-of-the-art tools using simulated cfDNA datasets with properties matching those of real cfDNA samples. The positive predictive value and sensitivity of our tool was superior to all the tested tools and reasonable performance was maintained down to the lowest dilution of 0.01% tumor DNA in simulated datasets. Additionally, SViCT was able to detect all known SVs in two real cfDNA reference datasets (at 0.6-5% ctDNA) and predict a novel structural variant in a prostate cancer cohort. AVAILABILITY: SViCT is available at https://github.com/vpc-ccg/svict. Contact:faraz.hach@ubc.ca.
MOTIVATION:Cancer is a complex disease that involves rapidly evolving cells, often forming multiple distinct clones. In order to effectively understand progression of a patient-specific tumor, one needs to comprehensively sample tumor DNA at multiple time points, ideally obtained through inexpensive and minimally invasive techniques. Current sequencing technologies make the 'liquid biopsy' possible, which involves sampling a patient's blood or urine and sequencing the circulating cell free DNA (cfDNA). A certain percentage of this DNA originates from the tumor, known as circulating tumor DNA (ctDNA). The ratio of ctDNA may be extremely low in the sample, and the ctDNA may originate from multiple tumors or clones. These factors present unique challenges for applying existing tools and workflows to the analysis of ctDNA, especially in the detection of structural variations which rely on sufficient read coverage to be detectable. RESULTS: Here we introduce SViCT , a structural variation (SV) detection tool designed to handle the challenges associated with cfDNA analysis. SViCT can detect breakpoints and sequences of various structural variations including deletions, insertions, inversions, duplications and translocations. SViCT extracts discordant read pairs, one-end anchors and soft-clipped/split reads, assembles them into contigs, and re-maps contig intervals to a reference genome using an efficient k-mer indexing approach. The intervals are then joined using a combination of graph and greedy algorithms to identify specific structural variant signatures. We assessed the performance of SViCT and compared it to state-of-the-art tools using simulated cfDNA datasets with properties matching those of real cfDNA samples. The positive predictive value and sensitivity of our tool was superior to all the tested tools and reasonable performance was maintained down to the lowest dilution of 0.01% tumor DNA in simulated datasets. Additionally, SViCT was able to detect all known SVs in two real cfDNA reference datasets (at 0.6-5% ctDNA) and predict a novel structural variant in a prostate cancer cohort. AVAILABILITY: SViCT is available at https://github.com/vpc-ccg/svict. Contact:faraz.hach@ubc.ca.
Authors: Teemu Kivioja; Anna Vähärautio; Kasper Karlsson; Martin Bonke; Martin Enge; Sten Linnarsson; Jussi Taipale Journal: Nat Methods Date: 2011-11-20 Impact factor: 28.547
Authors: Dorothee Pflueger; Stéphane Terry; Andrea Sboner; Lukas Habegger; Raquel Esgueva; Pei-Chun Lin; Maria A Svensson; Naoki Kitabayashi; Benjamin J Moss; Theresa Y MacDonald; Xuhong Cao; Terrence Barrette; Ashutosh K Tewari; Mark S Chee; Arul M Chinnaiyan; David S Rickman; Francesca Demichelis; Mark B Gerstein; Mark A Rubin Journal: Genome Res Date: 2010-10-29 Impact factor: 9.043
Authors: Jonathan C M Wan; Charles Massie; Javier Garcia-Corbacho; Florent Mouliere; James D Brenton; Carlos Caldas; Simon Pacey; Richard Baird; Nitzan Rosenfeld Journal: Nat Rev Cancer Date: 2017-02-24 Impact factor: 60.716
Authors: Jan Schröder; Arthur Hsu; Samantha E Boyle; Geoff Macintyre; Marek Cmero; Richard W Tothill; Ricky W Johnstone; Mark Shackleton; Anthony T Papenfuss Journal: Bioinformatics Date: 2014-01-02 Impact factor: 6.937
Authors: Ismail D Legason; Martin D Ogwang; Clara Chamba; Elifuraha Mkwizu; Claire El Mouden; Hadija Mwinula; Lulu Chirande; Anna Schuh; Faraja Chiwanga Journal: BMC Cancer Date: 2022-05-02 Impact factor: 4.638